A Fungal Halogenase or Preparation of new Halogenated Molecules

Utah State University is seeking an industry partner interested in licensing or collaborating to further develop an exciting new technology related to halogenating molecules for drug discovery and development.

  • Pharmaceuticals
  • Enzymatic activity
  • Biotechnology companies
  • Anti-fungal compounds
  • Anti-cancer compounds
  • Compound libraries
  • Anti-microbial discovery
  • Green chemistry

  • Halogenates diverse natural and non-natural products
  • Easy scale-up
  • Conducts both mono- and dihalogenation
  • Uses chloride or bromide as Halogen donors
  • Combats drug resistance issues

Commonly used antimicrobial agents are becoming less effective as bacteria continue to develop antibiotic resistance. One method to combat drug and antimicrobial resistance is to introduce small modifications (such as halogenation) to existing drugs, which can restore potency. Nearly 20% of drugs on the market and a quarter of new drugs in the development pipeline are halogented, clearly showing that halogenation can be a major advantage in new drug development. USU researchers have discovered an enzyme with unique halogenation activity which is useful for creation of new halogenated molecules for drug discovery. Specifically, the USU enzyme is useful for (i) producing halogenated compound libraries, and (ii) producing halogenated derivatives of compounds of interest. The enzyme is a powerful halogenating biocatalyst which can 1) halogenate a variety of natural and unnatural products; 2) conduct both mono- and dihalogenation; and 3) use both chloride and bromide as halogen donors.

Patent Information:
For Information, Contact:
Christian Iverson
Utah State University
Jixun Zhan